This full-time Master's programme provides a comprehensive overview of drug safety practices within the drug development process.
It addresses key aspects of preclinical drug evaluation through the study of:
It will give you state-of-the-art training in preclinical toxicology, with an emphasis on the molecular in vitro and in vivo aspects of toxicology and safety pharmacology assessments.
As part of the programme you will undertake an original research project that will be the basis of your dissertation.
Bradford, United Kingdom
IELTS: 6 TOEFL: 80
To be admitted to the programme, applicants must have an undergraduate Honours qualification (minimum 2: 2) or equivalent in a scientific discipline, usually within chemistry, biology, pharmacy, biomedicine, or related fields. Candidates who do not meet these entry criteria but who can show relevant experience may also be considered.
For North American students a GPA of normally 2.0 and above (on a scale of 4.0), or an equivalent, is required.
English language requirements
If your native language is not English, or official language of your first degree is not English, you will need to pass a test in English approved by the University before you can be admitted. The International English Language Testing System test (IELTS) administered by the British Council is the test which is preferred by the University.
You will need to achieve an overall score of at least 6.0, with at least 5.5 in each of the four sub-tests (speaking, listening, reading, writing). Testing facilities are available at most British Council overseas offices. When you take the test, you should ask for a copy of your Test Report Form to be sent to the University.
Alternative English language tests include:
The largest destination of our graduates is enrolment in PhD studies (47%) including here at Bradford, as well as King’s College London, Cambridge, Manchester, Liverpool, Leeds, Newcastle, Portsmouth and Sheffield.
Career destination of our graduates include the NHS, Covance, Envigo, St James Hospital Leeds, Cyprotex, Chiltern, Perrigo, Dewsbury & District Hospital, Liverpool Institute of Translational Medicine, and Public Health England.